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Hereditary haemochromatosis (HH) is the most common
lethal monogenic human disease, affecting roughly 1 in
300 white northern Europeans. Homozygosity for the
C282Y polymorphism within the HFE gene causes more
than 80% of cases, with compound heterozygosity of the
C282Y and H63D polymorphism also increasing suscepti-
bility to disease. The aim of this study was to determine the
frequency of the C282Y and H63D polymorphisms in the
disease, and to assess the risk of HH in heterozygotes for
the C282Y polymorphism. 128 patients were recruited
because of either radiographic chondrocalcinosis (at least
bicompartmental knee disease or joints other than the knee
involved) or CPPD pseudogout. Genotyping of the HFE
C282Y and H63D mutations was performed using
PCR/SSP and genotypes for the C282Y polymorphism
confirmed by PCR/RFLP. Historical white European control
data were used for comparison. Two previously undiag-
nosed C282Y homozygotes (1.6%), and 16 C282Y
heterozygotes (12.5%), including four (3.1%) C282Y/
H63D compound heterozygotes were identified. This rep-
resents a significant overrepresentation of C282Y
homozygotes (relative risk 3.4, p=0.037), but the number
of heterozygotes was not significantly increased. At a cost
per test of £1 for each subject, screening all patients with
chondrocalcinosis using the above ascertainment criteria
costs only £64 for each case of haemochromatosis identi-
fied, clearly a highly cost effective test given the early mor-
tality associated with untreated haemochromatosis.
Routine screening for haemochromatosis in patients with
appreciable chondrocalcinosis is recommended.
Hereditary haemochromatosis (HH) is one of the mostcommon inherited diseases, affecting about 300 peopleof northern European descent.1 It affects iron handling
and if untreated can result in cirrhosis of the liver, hepatocel-
lular carcinoma, diabetes mellitus, cardiomyopathy, and other
conditions resulting in premature death. Three distinct genetic
subsets of haemochromatosis have been characterised so far.
Type 2 HH has been mapped to chromosome 1q (HFE2), is
primarily involved with juvenile haemochromatosis,2 and has
not been related to the more common later onset disease. Type
3 is associated with mutations; Camaschella et al3 identified a
Tyr to stop signal substitution at codon 250 of the transferrin
receptor-2 (TFR2) gene in two Sicilian families and linkage
analysis subsequently established a locus at chromosome 7q22
(HFE3). Recently, twomore genes involved in ironmetabolism
have been linked to HH. A mutation within the gene SLC11A3
(solute carrier family 11 A3) was found in all affected
members of a large Dutch family.4 A point mutation of the iron
response element motif of H-ferritin mRNA5 has also been
reported to increase cellular iron uptake in a Japanese family.
However, by far the most common form is type 1 HH, which is
caused by mutations of the HFE gene, and is mapped to
6p21.3.6 Over 80% of patients with HH are homozygous for a
mutation at codon 282, which results in a Cys to Tyr substitu-
tion that inhibits HFE/β2-microglobulin binding.7 A second
mutation within the gene at codon 63 (His to Asp) is also
associated with HH when inherited in combination with the
C282Y mutation,8 where compound heterozygosity for the two
mutations results in increased susceptibility to disease. About
90% of C282Y homozygotes and 38% of H63D/C282Y
heterozygotes develop haemochromatosis, and C282Y hetero-
zygotes have also been shown to exhibit minor abnormalities
of iron overload. Heterozygosity for the C282Y variant has
been associated with porphyria cutanea tarda,9 coronary heart
disease,10 and type 2 diabetes11 in some but not all studies.
Chondrocalcinosis is a common rheumatic disease charac-
terised by deposition of calcium salts in the joint cartilage,
commonly calcium pyrophosphate dihydrate or calcium
hydroxyapartite. Chondrocalcinosis may occur as a complica-
tion of various conditions including hyperparathyroidism,
haemochromatosis, hypothyroidism, and Wilson’s disease12;
between 30% and 50% of patients with haemochromatosis
also have chondrocalcinosis.
Previous studies examining the frequency of haemochro-
matosis in chondrocalcinosis have not used genetic screening.
The aim of this study was to determine the frequency of
genetic haemochromatosis in chondrocalcinosis and to assess
the risk of disease in heterozygotes for the C282Y polymor-
phism.
PATIENTS AND METHODS
Patients
A total of 128 patients (70 male and 58 female) were recruited
from the Nuffield Orthopaedic Centre. Patients were recruited
because of either radiographic chondrocalcinosis (at least
bicompartmental knee disease or involvement of joints other
than the knee (82 (64%) patients)) or calcium pyrophosphate
dihydrate pseudogout (46 (36%) patients). Ages ranged from
28 to 89 years, mean 64.7 years. Patients were recruited
irrespective of whether they had previously been screened for
metabolic diseases associated with haemochromatosis. None
of the patients had previously been diagnosed as having iron
overload.
Laboratory and statistical methods
A polymerase chain reaction using sequence specific primers
(PCR/SSP)13 was used to identify alleles at both polymor-
phisms within codons 63 and 282 (fig 1). Results at codon 282
were confirmed by PCR using restriction fragment length
polymorphism (PCR/RFLP).14 Historical white controls of
European descent were used for comparison.15 The controls
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were genotyped as part of a large community survey and are
therefore not significantly affected by ascertainment bias. This
problem may lead to underestimation of haemochromatosis
gene frequencies when exclusion of diagnosed cases may
inadvertently have occurred.
Relative risk of genotypes was determined by standard
methods.16
RESULTS
Results for both polymorphisms in comparison with the
historical white controls are shown in table 1. We identified
two previously undiagnosed C282Y homozygotes (1.6%) in
patients compared with 16 of 3011 controls (0.5%). This rep-
resents a significant overrepresentation of C282Y homo-
zygotes (relative risk 3.4, p=0.037). We also identified four
C282Y/H63D compound heterozygotes (3.1%), a similar
proportion to the normal control population (2.2%). There was
also no significant difference in the number of C282Y hetero-
zygotes (12.5% in the patient group v 11.9% in the control
group). Genotyping results of codon 282 were consistent with
PCR/SSP and PCR/RFLP in all 128 patients.
The genotyping cost for each patient was £1, representing
the consumable costs for DNA extraction, PCR/RFLP, and
PCR/SSP; thus in this subset of patients with chondrocalcino-
sis the cost for each C282Y homozygote discovered was £64.
DISCUSSION
This study confirms the association of haemochromatosis
caused by homozgosity for the C282Y HFE variant, with
significant chondrocalcinosis, as defined by ascertainment
criteria for this study. Although haemochromatosis remains
an uncommon cause of chondrocalcinosis, it is sufficiently
frequent that screening for haemochromatosis is clearly
worthwhile in patients with appreciable chondrocalcinosis.
However, whether screening patients with less severe chon-
drocalcinosis is worthwhile is uncertain. Previous studies have
shown that patients with haemochromatosis and chondro-
calcinosis are younger and more likely to be male than
patients with chondrocalcinosis not associated with
haemochromatosis.17 18 Screening elderly patients with mild
chondrocalcinosis may not therefore be as worthwhile.
We found no association of chondrocalcinosis with geno-
types causing less severe concentrations of iron overload, such
as C282Y/wild-type and C282Y/H63D heterozygote genotypes.
This indicates that unlike the situation in porphyria cutanea
tarda, mild degrees of iron overload are not sufficient to cause
chondrocalcinosis. The study had 80% power to detect an
association (for p<0.05, one tailed) with C282Y heterozygotes
with an odds ratio of less than 1.9, and an association with
C282Y/H63D compound heterozygotes with an odds ratio of
less than 3.2. Thus associations of smaller magnitude may not
have been found in this study.
Previous modelling of cost effectiveness of screening for
haemochromatosis has suggested that screening is cost effec-
tive if the prevalence of disease in the screened population was
equal to 3/1000, the positive predictive value of the diagnostic
test was less than 0.4, and the test cost was less than $12.19 The
positive predictive value of C282Y screening is more than 80%,
and the cost of the genetic test in our laboratory is about £1,
well within the values required for screening to be cost effec-
tive. Although further studies are required to confirm our
findings, this study suggests that there is a strong argument
for widespread genetic screening for haemochromatosis in
patients with appreciable chondrocalcinosis and onset of
chondrocalcinosis at an early age.
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Figure 1 A polymerase chain reaction with sequence specific primers (PCR/SSP)13 was used to identify alleles at both polymorphisms within
codons 63 and 282.
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Table 1 HFE polymorphism genotypes in patient and
historical control populations
Genotype
Patients
n (%)
Historical controls
n (%)
C282Y/C282Y 2(1.6)* 16(0.5)
C282Y/wild-type 16(13) 359(12)
C282Y/H63D 4(3.1) 65(2.2)
Other 110(86) 2636(88)
Total 128 3011
*Relative risk 3.4, p=0.037.
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CORRECTION
Genetic testing for haemochromatosis
in patients with chondrocalcinosis (Ann
Rheum Dis 2002;61:745–7.)
The authors regret that owing to an
administrative oversight B P Wordsworth was
omitted as one of the authors of this paper.
The correct listing of authors is a follows:
A E Timms, R Sathananthan, L Bradbury,
N A Athanasou, B P Wordsworth, MA Brown.
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